Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coloplast ASCLPBY -1.32%77 Cash-to-Debt is 0.04 as of Mar. 2026, which is 76% below its 10-year median of 0.17. GuruFocus rates CLPBY with a GF Score™ of 77/100 and a GF Value™ of $13.05 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 849 Medical Devices & Instruments companies, Coloplast AS ranks worse than 96.35% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Coloplast AS's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.04.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Coloplast AScouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Coloplast AS's Cash-to-Debt or its related term are showing as below:
CLPBY'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.17 Max: 4.64
Current: 0.04
During the past 13 years, Coloplast AS's highest Cash to Debt Ratio was 4.64. The lowest was 0.03. And the median was 0.17.
CLPBY's Cash-to-Debt is ranked worse than 96.35% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.64
vs CLPBY: 0.04
Coloplast AS (OTCPK:CLPBY) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Coloplast AS Cash-to-Debt Related Terms
Coloplast AS Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Coloplast AS's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Instruments & Supplies subindustry, Coloplast AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Coloplast AS's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coloplast AS (CLPBY) has a Cash-to-Debt of 0.04 as of Mar. 2026. This is 76% below median its historical median of 0.17. Over the past decade, Coloplast AS's Cash-to-Debt has ranged from 0.03 to 4.64. According to the industry distribution chart, Coloplast AS ranks #818 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 96.3%.
Is Coloplast AS's Cash-to-Debt too high?
Coloplast AS's current Cash-to-Debt of 0.04 is 76% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 4.64. The Medical Devices & Instruments industry median Cash-to-Debt is 1.64. Coloplast AS's value of 0.04 is 97.6% below this industry median. Based on the distribution chart, Coloplast AS ranks #818 out of 849 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Coloplast AS has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's Cash-to-Debt compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #818 out of 849 companies for Cash-to-Debt. This places Coloplast AS in the lower half of its industry. The industry median Cash-to-Debt is 1.64. Coloplast AS's value of 0.04 is 97.6% below this benchmark. Historically, Coloplast AS's own Cash-to-Debt has ranged from 0.03 to 4.64 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 1.64, Coloplast AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.64, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coloplast AS's current Cash-to-Debt of 0.04 is 97.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current Cash-to-Debt is 0.04, which is 76% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBY) is currently considered Significantly Undervalued. The stock's GF Value™ is $13.05, compared to a current price of $6.71 — trading 48.6% below its estimated fair value. The current Cash-to-Debt is 0.04, which is 76% below median its 10-year median of 0.17 and 97.6% below the Medical Devices & Instruments industry median of 1.64. Coloplast AS's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Coloplast AS (CLPBY), the current Cash-to-Debt is 0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBY) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $6.71 is trading 48.6% below its estimated GF Value™ of $13.05.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBY:
Cash-to-Debt: 0.04 (76% below median its 10-year median of 0.17)
GF Value™: $13.05 vs. price of $6.71 (48.6% below fair value)
Industry Position: 97.6% below the Medical Devices & Instruments median (#818 of 849)
No single metric tells the full story. See the CLPBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
77GF Score
Get the complete analysis for CLPBY
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBY has been successfully added to your 
